论文部分内容阅读
3例癫痫患者（例1女，60岁，有心脏病史；例2男，29岁；例3男，18岁）均因癫痫发作口服奥卡西平（例1:0.3 g、2次/d，例2:0.45 g、2次/d，例3:0.6 g、2次/d），例1、例2和例3分别在用药4、5、1 d后出现间断性晕厥或心悸。3例患者的心电图检查结果均提示心律失常，例1出现心房颤动、心脏停搏、Ⅲ度窦房传导阻滞、Ⅱ度Ⅱ型房室传导阻滞，例2、例3出现不同程度的房室传导阻滞，考虑为奥卡西平所致心脏毒性反应。例1停用奥卡西平3 d后晕厥次数由2~3次/d减至1次/d，复查心电图仍有Ⅱ度Ⅱ型房室传导阻滞，在心脏科行心脏起搏器植入术后未再出现晕厥。例2停用奥卡西平5 d后未再发生晕厥。例3将奥卡西平减量至0.45 g、2次/d并加用其他抗癫痫药物2 d后未再出现心悸。“,”Three patients with epilepsy (patient 1, a 60-year-old female with a history of heart disease; patient 2, a 29-year-old male; patient 3, an 18-year-old male) received oxcarbazepine orally for epileptic seizures (patient 1 received 0.3 g twice daily; patient 20.45 g twice daily; patient 3 0.6 g twice daily). Intermittent syncope or palpitations occurred in patient 1, 2, and 3 on day 4, 5, and 1 after medications, respectively. All 3 patients showed arrhythmias in electrocardiograms. Patient 1 developed atrial fibrillation, cardiac arrest, degree III sinoatrial block, degree II type II atrioventricular block; patient 2 and 3 developed different degrees of atrioventricular block. Above-mentioned arrhythmias were considered to be cardiotoxicity caused by oxcarbazepine. In patient 1, the number of syncope was reduced from 2 to 3 times per day to 1 time per day after 3 days of oxcarbazepine withdrawal, but the electrocardiogram still showed degree II type II atrioventricular block. Then no syncope recurred after implantation of heart pacemaker. In patient 2, no syncope recurred after 5 days of oxcarbazepine withdrawal. In patient 3, no palpitations recurred after reduction of oxcarbazepine to 0.45 g twice daily and addition of other antiepileptic drugs for 2 days.